190 related articles for article (PubMed ID: 9457393)
1. Interleukin-2 therapy in relapsed acute myelogenous leukemia.
Meloni G; Vignetti M; Pogliani E; Invernizzi R; Allione B; Mirto S; Sica S; Leoni F; Selleri C; Mandelli F
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S43-7. PubMed ID: 9457393
[TBL] [Abstract][Full Text] [Related]
2. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.
Zittoun RA; Mandelli F; Willemze R; de Witte T; Labar B; Resegotti L; Leoni F; Damasio E; Visani G; Papa G
N Engl J Med; 1995 Jan; 332(4):217-23. PubMed ID: 7808487
[TBL] [Abstract][Full Text] [Related]
3. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission.
Blaise D; Attal M; Reiffers J; Michallet M; Bellanger C; Pico JL; Stoppa AM; Payen C; Marit G; Bouabdallah R; Sotto JJ; Rossi JF; Brandely M; Hercend T; Maraninchi D
Eur Cytokine Netw; 2000 Mar; 11(1):91-8. PubMed ID: 10705305
[TBL] [Abstract][Full Text] [Related]
4. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
van Besien K; Margolin K; Champlin R; Forman S
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
[TBL] [Abstract][Full Text] [Related]
5. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) Leukemia Cooperative Groups.
Keating S; Suciu S; de Witte T; Mandelli F; Willemze R; Resegotti L; Broccia G; Thaler J; Labar B; Damasio E; Bizzi B; Rotoli B; Vekhoff A; Muus P; Petti MC; Dardenne M; Solbu G; Vegna ML; Zittoun RA
Bone Marrow Transplant; 1996 Jun; 17(6):993-1001. PubMed ID: 8807105
[TBL] [Abstract][Full Text] [Related]
7. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
Stone RM; DeAngelo DJ; Janosova A; Galinsky I; Canning C; Ritz J; Soiffer RJ
Am J Hematol; 2008 Oct; 83(10):771-7. PubMed ID: 18756547
[TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
[TBL] [Abstract][Full Text] [Related]
9. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
10. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
[TBL] [Abstract][Full Text] [Related]
11. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
Tallman MS; Lee S; Sikic BI; Paietta E; Wiernik PH; Bennett JM; Rowe JM
Cancer; 1999 Jan; 85(2):358-67. PubMed ID: 10023703
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
Zhang WG; Wang FX; Chen YX; Cao XM; He AL; Liu J; Ma XR; Zhao WH; Liu SH; Wang JL
Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614
[TBL] [Abstract][Full Text] [Related]
13. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
Bassan R; Raimondi R; Lerede T; D'emilio A; Buelli M; Borleri G; Personeni A; Bellavita P; Rodeghiero F; Barbui T
Haematologica; 1998 Jul; 83(7):627-35. PubMed ID: 9718868
[TBL] [Abstract][Full Text] [Related]
14. Outcome of patients with acute myelogenous leukemia after second salvage therapy.
Giles F; O'Brien S; Cortes J; Verstovsek S; Bueso-Ramos C; Shan J; Pierce S; Garcia-Manero G; Keating M; Kantarjian H
Cancer; 2005 Aug; 104(3):547-54. PubMed ID: 15973664
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-2 before and/or after autologous bone marrow transplantation for pediatric acute leukemia patients.
Messina C; Zambello R; Rossetti F; Gazzola MV; Varotto S; Destro R; Basso G; Semenzato G; Zanesco L
Bone Marrow Transplant; 1996 May; 17(5):729-35. PubMed ID: 8733689
[TBL] [Abstract][Full Text] [Related]
16. A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-alpha) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantation.
Nagler A; Berger R; Ackerstein A; Czyz JA; Diez-Martin JL; Naparstek E; Or R; Gan S; Shimoni A; Slavin S
J Immunother; 2010 Apr; 33(3):326-33. PubMed ID: 20445353
[TBL] [Abstract][Full Text] [Related]
17. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S
Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission.
Cortes JE; Kantarjian HM; O'Brien S; Giles F; Keating MJ; Freireich EJ; Estey EH
Cancer; 1999 Apr; 85(7):1506-13. PubMed ID: 10193940
[TBL] [Abstract][Full Text] [Related]
19. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
Pastore D; Specchia G; Carluccio P; Liso A; Mestice A; Rizzi R; Greco G; Buquicchio C; Liso V
Ann Hematol; 2003 Apr; 82(4):231-5. PubMed ID: 12707726
[TBL] [Abstract][Full Text] [Related]
20. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
